Soft tissue sarcomas (STSs) represent a diverse group of tumors that pose significant diagnostic and therapeutic challenges. In a recent review published in the KeAi journal Meta-Radiology, a team of ...

A systematic review finds that diagnostic discordance in bone and soft tissue sarcoma may reduce survival, supporting expert second opinions. STS is a rare cancer that originates as an abnormal growth ...

Results presented here showed negative pressure wound therapy is a safe adjunct for soft tissue sarcoma treated with ...

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 24, Iovance Biotherapeutics announced positive early data from a pilot ...

Sarcoma originates in connective tissues, with soft tissue and bone sarcomas as primary categories, each having multiple subtypes. Staging considers tumor size, grade, and metastasis, guiding ...

Novel biomarkers like GDF15 and OPN show promise in diagnosing and prognosticating uterine sarcoma, potentially enabling early identification and tailored therapy. Blood-based markers such as NLR and ...

Treatment with doxorubicin plus trabectedin (Yondelis), followed by trabectedin maintenance, improved overall survival (OS) and progression-free survival (PFS) in patients with metastatic or ...

Prognostic factors in soft tissue sarcomas encompass a diverse spectrum of clinical, pathological and host-related parameters that influence patient outcomes. Increasingly, research is demonstrating ...

Angiosarcoma is an aggressive malignancy derived from endothelial cells, characterised by its rapid progression, heterogeneity and distinct clinical challenges. As a subset of soft tissue sarcomas, ...

Doctors stage Ewing sarcoma by considering its size, whether it affects lymph nodes, and whether it has spread to other areas. It always has a high grade, meaning that the cancer looks highly atypical ...

University of Maryland School of Medicine researchers are investigating a new approach to treat high-risk soft-tissue sarcomas by combining two immunotherapy drugs with radiation therapy to stimulate ...

Among the key speakers was Associate Professor Johnny Ong, Head and Senior Consultant of the Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT) at the National Cancer Cen ...